Pharmaceutical companies lost more than 3.5 billion de-listed pit cry nearly 50,000 shareholders! Hundreds of billions of "medical Maotai" suddenly fell to a halt.

Recently, the market value of 100 billion "Pharma Maotai" Changchun high-new stock price suddenly stopped, 4 days market value evaporated more than 20 billion; By the Shenzhen Stock Exchange delisted, a record decline in A-shares, a plunge of 99.75 percent, data show that chiyama machine has nearly 50,000 shareholders, in recent years the company is deeply involved in annual report fraud, occupation of funds, the last three years of net profit losses totaled more than 3.5 billion yuan, and now in the capital market finally ended in de-listing.
, the A-share market, Hengrui Pharmaceuticals, Meirui Medical, Pharmaceutical Mingkangde, Zhifei Bio, Chipoand other 10 pharmaceutical stock market value of more than 100 billion scale.
As of the close of trading on September 18, Hengrui Pharmaceuticals was still in the top spot with a market capitalisation of 472.2 billion yuan, followed by Meirui Medical, and the market capitalisation ofsurpassed that of Yunnan White Pharmaceuticals as the market capitalization leader in the Chinese medicine sector.
pharmaceutical stock market value TOP20 pharmaceutical stocks TOP20 ranking change! Hengrui retreated to a market capitalization of 470 billion yuan, "Chinese medicine stocks a brother" easy to master in November 2017, Hengrui Pharmaceuticals became the first pharmaceutical stocks with a market value of more than 200 billion yuan; It exceeded 300 billion yuan; in October 2019, the market value broke through 400 billion yuan; and in June this year, the market value hit a new high of more than 500 billion yuan, firmly in the "pharmaceutical stocks" throne.
the recent correction in various sectors of the A-share market, as of the close of trading on September 18, Hengrui Pharmaceutical's market value fell back to 472.2 billion yuan, up more than 20% so far this year.
the market value of Murray Healthcare has soared by more than 170 billion yuan so far this year, and compared with last year, the gap between the market value of Hengrui Pharmaceuticals and Meirui Medical has narrowed from more than 160 billion yuan to less than 80 billion yuan.
, Murray Healthcare landed on A-shares in October 2018, with a market capitalisation of more than 200 billion yuan a year after listing;
market value of Myer Healthcare fell back to $393.7 billion by the close of trading on September 18.
In addition, "Chinese medicine stocks a brother" easy owner, in early September, the market value of theonce exceeded 160 billion yuan, this year has surged nearly 100 billion yuan, and then fell back to 147.4 billion yuan, surpassing Yunnan white medicine, become the market value of the Chinese medicine sector leader.
hundreds of billions of "medical Maotai" suddenly fell to a halt! 4 days of market value evaporated more than 20 billion September 14, known as "Pharma Maotai" Changchun high-rise stock price fell, from the news, because of a research rumors; In the first three quarters of 2020, the company forecast earnings of RMB2,171 million-RMB2.295 billion, up 75%-85% YoY, with the main reason for the increase in net profit due to the revenue growth of the holding backbone pharmaceutical enterprises and the co-schedule of Changchun Jinsai Pharmaceuticals.
On the same day, Changchun Gaoxin received a letter of concern from the Shenzhen Stock Exchange, requesting that the company's second largest shareholder in the Jinsai Pharmaceuticals research conference published "other urban marketing model is still problematic, bad in the third quarter also has internal reasons for lax, July year-on-year decline", "Kinsey Pharmaceuticals next year's performance outlook from 35% growth to 2 5%" and other related to the company's main subsidiary Jinsai Pharmaceutical performance, "due to the need to pay 1 billion yuan in taxes, the end of the year will do a reduction" and other statements about the reduction of the company's shares, as well as "whether the company has selectively, privately disclosed to specific shareholders, leakage or disclosure of non-public information, whether there is a violation of the principle of fair disclosure of information" and other issues to further explain.
changchun high-rise in four trading days, the market value evaporated more than 20 billion yuan, as of the close of September 18, the market value of 146.5 billion yuan, up more than 60% so far this year.
in August this year, Changchun High-new stock price once exceeded 500 yuan, the market value of more than 200 billion mark.
, there are two main views on the volatility of Changchun High-new stock prices.
First, the media reports of research events company executives gave less than expected performance guidance, as well as the future of the arrangements for senior executives to reduce holdings, triggered investors' concerns;
September 16, Changchun Gaoxin said on the interactive platform, the company level has not received relevant research, please pay attention to the company announcement and so on.
statistics, 14-16, in the interactive platform and the investigation of the event-related questions as many as 30.
200 billion market capitalization is only 20 billion! State-owned conmedicine pharmaceutical industry, 9 consecutive board rise and stop after the re-emergence of the "sky floor" on the evening of September 2, ST Kangmei (Conme Pharmaceuticals) issued a notice that Jieyang Yilin Pharmaceutical Investment Co., Ltd. (referred to as: Yilin Investment) to be the company's controlling shareholder Kangmei Industrial Investment Holdings Co., Ltd. (referred to as: Kangmei Industrial) held 29.9% of the shares corresponding to the voting rights.
the transaction is completed, STCom's controlling shareholder will be changed to Yilin Investment and the Company will have no actual controller.
Yilin Investment was established in August 2020 and its three shareholders are Jieyang City Investment and Construction Group Co., Ltd., Guangdong Jinsu Equity Trust Center Co., Ltd. and Guangzhou Shennon's Chinese Medicine Development Co., Ltd.
from the timing of Yilin's investment, the purpose is likely to be to host Comey Pharmaceuticals.
combined with the background of the three shareholder enterprises, in the Chinese medicine industry for many years, and has experience in the operation of listed pharmaceutical companies, the Broad Pharmaceutical Group is likely to be responsible for specific operations.
, Comm pharmaceutical company went public in 2001 and its market capitalisation exceeded $100 billion in 2018, according to the company.
, Kangmei Pharmaceuticals announced its first-half 2020 results, with revenue of 2.517 billion yuan and a net profit loss of 1.424 billion yuan.
September 3, ST Kangmei resumed trading, stimulated by this good news, for 9 consecutive trading days, during which ST Kangmei issued a number of risk warning announcements due to the continuous rise and fall of the stock price; When the 10th rally was in the bag, the share price suddenly plunged and ended the day with a "sky floor" to close down; on September 17th ST Camey continued to fall; and as of September 18th, it had a market capitalisation of $20bn.
to this, some industry analysts pointed out that, because the fundamentals of ST shares are poor, investors should pay attention to risk, to rational view, careful analysis of its causes and effects, to avoid blind pursuit, follow the hype, resulting in unnecessary losses.
fell by a record A-share! The pharmaceutical stock plunged 99.75 percent to the market, pit cry nearly 50,000 shareholders on September 15, Qianshan retreat (thousand yam medicine machine) issued a notice that the company's shares on August 5, 2020 into the de-listed finishing period, as of September 15 has completed 30 trading days, the de-listed finishing period has ended.
company's shares have been suspended by the Shenzhen Stock Exchange and will be delisted on September 16.
thousand yam machine from entering the de-market consolidation period of the stock price began 29 consecutive one-word decline, the final share price was fixed at 0.19 yuan, compared with the historical high of 99.75 percent, the largest decline in A-shares record.
It is understood that in the 2015-2016 annual report, Chishan Pharmaceutical Machine has a false reduction in accounts receivable, bad debt preparation, inflated profits and other circumstances, the two-year inflated profit totaled more than 400 million yuan;
as of May 2020, Chiyama Pharmaceuticals had 482,000 shareholders.
data show that Chiyama pharmaceutical machine landed in A shares in 2011, in 2015, the company officially dabbled in slow disease management, followed by the detection of gene chips, wearable devices and APP products.
with thousands of yam machines constantly close to genetic testing, big health and other hot concepts, its market value once approached 30 billion yuan.
: Oriental Wealth Network, listed companies announced the original title: pharmaceutical companies lost more than 3.5 billion de-listed, pit cry nearly 50,000 shareholders! Hundreds of billions of "pharmaceutical Maotai" suddenly fell to a halt, pharmaceutical stocks TOP20 ranking change.